Search Results 151-160 of 16772 for GLP-1 agonists
Subject has type 1 diabetes for more than one year Study specific inclusion criteria. ... Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP agonists ...
... glucagon-like peptide (GLP)- 1 agonists, or insulin. Dose changes of these medications are allowed in the 6 months prior to diagnostic liver biopsy, except ...
... 1 trial. Phase 4 trials look at ... Antihyperglycemic agents, including subcutaneous insulin therapy, sulfonylureas, SGLT2 inhibitors, and GLP-1 agonists ...
Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis ...
... 1 trial. Phase 4 trials look at long-term safety and effectiveness, after ... Note: Glucagon-like peptide-1 (GLP-1) receptor agonists may be used up to ...
Benefits of Glucagon-like Peptide-1 Receptor Agonists After Kidney Transplantation. Endocr Pract. 2025 Jun; 31 (6):798-804 Epub 2025 Mar 05. View PubMed ...
The IGF-1 blood test measures the level of insulin-like growth factor 1 (IGF-1) in your blood. ... Dopamine agonists. Cabergoline and bromocriptine ... 1 levels, ...
This medicine does not help patients who have insulin-dependent or type 1 diabetes. This medicine is available only with your doctor's prescription. This ...
If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. ... You may report side effects to ...
Impact of Glucagon-Like Peptide-1 Receptor Agonist Exposure on Gastrointestinal Outcomes Among ICU Patients: A Multicenter Matched Cohort Study. Crit Care ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.